Medical management of pulmonary disease caused by Mycobacterium avium complex.
The current medical therapy for Mycobacterium avium complex is controversial. American Thoracic Society recommendations advocate empiric therapy with drug susceptibility testing only for clarithromycin. At National Jewish, where we mainly see cases complicated by treatment failure and drug intolerance, we use in vitro susceptibility testing and therapeutic drug monitoring to optimize efficacy and reduce toxicity.
Iseman
Michael D
MD
Clinical Mycobaceteriology Service, Infectious Diseases Section, University of Colorado School of Medicine, 4200 East Ninth Avenue, Denver, CO 80262, USA. isemanm@njc.org
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D006801:Humans; D008826:Microbial Sensitivity Tests; D015269:Mycobacterium avium Complex / Q000472:pathogenicity*; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy* / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents